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The maximal aerobic exercise capacity of patients with 
chronic heart failure is frequently decreased because of 
inadequate blood flow to working skeletal muscle. To 
investigate whether this reduced flow is in part due to 
interference by angiotensin II with arteriolar dilation in 
working muscle, the effect of the angiotensin-converting 
enzyme inhibitor captopril on leg blood flow, leg vascular 
resistance, leg oxygen consumption ('V02) and leg lactate 
release during maximal upright bicycle exercise was ex-
amined in 12 patients with heart failure (maximal V02 
10.7 ± 3.1 mllmin per kg). Captopril decreased leg 
resistance at rest (258 ± 115 to 173 ± 67 U, P < 0.01) 
and maximal exercise (68 ± 69 to 45 ± 29 U, P < 0.01) 
Patients with chronic heart failure are frequently limited 
during maximal exercise even when they are asymptomatic 
at rest (1-4). Prior observations (1-7) indicate that this 
exercise intolerance is frequently due to a decrease in blood 
flow to working skeletal muscle with consequent muscular 
fatigue. Therefore, to develop therapeutic strategies for im-
proving the maximal exercise capacity of patients with heart 
failure, it is important that the mechanism responsible for 
this decrease in blood flow to muscle be identified. 
Previous observations suggest that impaired dilation of 
resistance vessels within working muscle may be an im-
portant contributor to this decreased muscle flow. We have 
noted (4) that leg vascular resistance does not decrease nor-
mally during maximal upright bicycle exercise in patients 
with severe heart failure. Zelis et al. (7) reported that fore-
arm vascular resistance does not decrease normally during 
forearm exercise in patients with heart failure. 
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associated with proportionately similar decreases in sys-
temic vascular resistance. However, maximal exercise 
duration and maximal V02 were unchanged and, at 
identical peak exercise work times, there was no im-
provement in leg blood flow (2.0 ± 0.9 to 2.0 ± 1.1 
liters/min, p = NS), leg V02 (261 ± 104 to 281 ± 157 
ml/min, p = NS) or leg lactate release (269 ± 149 to 
227 ± 151 mg/min, p = NS). These data suggest that, 
during exercise in patients with heart failure, angioten-
sin II does not interfere with blood flow to working skel-
etal muscle. 
(J Am Coil CardioI1985;6:556-63) 
One potential contributor to impaired vasodilation in 
working muscle is the renin-angiotensin system. In patients 
with heart failure, the renin-angiotensin system is frequently 
more activated than in normal subjects at rest (8,9) and 
during exercise (10, II). Angiotensin II is a potent vasocon-
strictor of skeletal muscle arterioles by a direct effect (12-14) 
and augmentation of sympathetically mediated vasocon-
striction (15). Such vasoconstrictor influences could inter-
fere with the metabolic vasodilation that normally plays a 
key role in augmenting blood flow to working muscles. The 
present study was undertaken to investigate this specific 
hypothesis and to investigate the contribution of the renin-
angiotensin system to limb vascular resistance in patients 
with heart failure. 
Methods 
Patients. Twelve men with chronic left ventricular dys-
function (ejection fraction 18 ± 9%) were studied. Their 
mean age was 58 ± 12 years. All patients had exertional 
breathlessness or fatigue, or both, despite administration of 
digoxin and diuretic drugs and all were classified in New 
York Heart Association functional class III. None had pe-
ripheral edema, ascites, angina pectoris, intermittent clau-
dication or reduced pulses in his legs at the time of study. 
Before enrollment in this study, all patients were optimally 
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diuresed by increasing diuretic drug dosage until evidence 
of fluid retention was gone or until mild prerenal azotemia 
was noted. All patients had a reduction in maximal oxygen 
uptake to less than 20 ml/min per kg (average 10.7 ± 3.1, 
range 5.3 to 16.3 mllmin per kg). Left ventricular dys-
function was attributed to coronary artery disease in eight 
patients and to idiopathic dilated cardiomyopathy in four 
patients. No patient had received any vasodilator for at least 
I week. The protocol was approved by the Committee on 
Studies Involving Human Subjects at the University of Penn-
sylvania. Written informed consent was obtained from all 
subjects. 
Protocol. On the day before study, a trial maximal ex-
ercise test was performed to acquaint the patient with the 
exercise protocol. Data accumulated from this trial test were 
discarded. Exercise was performed on an upright mechan-
ically braked bicycle ergometer (Monarch) and begun at a 
work load of 20 W. Every 3 minutes the work load was 
increased by 20 W to symptomatic maximum. All exercise 
tests were performed at least 4 hours after the patient had 
eaten a meal. 
The following morning, digoxin and diuretic drugs were 
withheld. A Swan-Ganz catheter was inserted by way of an 
antecubital vein and positioned in the pulmonary artery. A 
short polyethylene catheter was inserted in a radial artery. 
A 5F thermodilution catheter was inserted percutaneously 
into the left femoral vein and advanced 15 to 16 cm antero-
grade into the iliac vein. 
Thirty minutes after instrumentation, hemodynamic mea-
surements were made and blood samples were obtained from 
the radial artery and femoral vein catheters for oxygen sat-
uration and lactate concentration. Femoral vein blood flow 
was measured in triplicate. Respiratory gases were measured 
with a Beckman Metabolic Cart equipped with oxygen and 
carbon dioxide analyzers and a turbine volume transducer. 
The patient then mounted the bicycle and, after a 5 minute 
equilibration period, measurements were repeated. 
The patient then began exercise. Respiratory gas and 
hemodynamic measurements were made continuously. Dur-
ing each 3 minute exercise stage, leg blood flow was mea-
sured every 30 seconds starting at 30 seconds and continuing 
up to 2.5 minutes (total of five measurements). The average 
of these five measurements was then taken as the mean flow 
for the exercise stage. Blood sampling was performed during 
the last 30 seconds of the stage. Leg flow was not measured 
during this period. 
Exercise after captopril. After exercise was terminated, 
the patient was allowed to rest for 1 hour. Captopril was 
then administered orally at a dose of 6.25 mg. At the end 
of 1 hour, repeat supine and upright hemodynamic mea-
surements were made. If the upright systolic blood pressure 
was decreased by greater than 15 mm Hg, no further cap-
topril was administered. After an additional 1 hour wait to 
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assure full recovery from the first exercise period, exercise 
was repeated. If the change in blood pressure was less than 
15 mm Hg, an additional 18.75 mg dose of captopril was 
administered. Hemodynamic data were measured 1 hour 
after this second dose. If the upright systolic blood pressure 
was now decreased by greater than 15 mm Hg, exercise 
was repeated. If the blood pressure change was less than 
15 mm Hg, an additional 25 mg dose of captopril was 
administered. One hour later, exercise was repeated. Total 
captopril dose averaged 20 ± 14 mg (6.25 mg for five 
patients, 25 mg for six patients and 50 mg for one patient). 
The time between the two exercise tests was 3 hours in 11 
patients and 4 hours in the 1 patient who received 50 mg 
of captopril. 
During the second exercise test, hemodynamic and met-
abolic measurements were made at exercise times identical 
to those during control exercise. If a patient exercised longer 
after captopril administration, measurements were also made 
at the new maximal exercise level. 
After a single dose of captopril, blood levels and hemo-
dynamic effects peak at 1 to 2 hours (16). Hemodynamic 
and free captopril levels then decrease progressively over 4 
hours. Therefore, when multiple captopril doses are ad-
ministered over 2 to 3 hours, the effect of the first dose may 
be dissipating as the effect of the last dose peaks. Hemo-
dynamic measurements, therefore, were made every 30 min-
utes. At the time of the repeat exercise test, there was no 
evidence that the hemodynamic effects of captopril had peaked 
and begun to dissipate. Converting enzyme inhibition should 
have produced parallel reductions in angiotensin II. The 
circulating half-life of angiotensin II is approximately 1 
minute, so that a steady state level of converting enzyme 
inhibition should produce a steady state angiotensin II level 
in a short time. 
In three patients, leg blood flow was not measured during 
exercise because of technical difficulties. Femoral vein ef-
fluent, however, was measured in all patients both at rest 
and during exercise. 
Leg blood flow. Leg blood flow was determined by the 
thermodilution method described by 10rfeldt et al. (17-19) 
and previously utilized by our laboratory (4,20,21). In brief, 
femoral vein flow was measured using a 50 cm 5F ther-
modilution catheter with the thermistor at 2 cm and injection 
port 12 cm from the tip. Flow was determined using rapid 
injection of a 2.5 ml iced dextrose bolus injectate and a 
commercially available thermodilution computer (Elecath). 
Output curves were displayed on a strip chart recorder to 
assure an exponential decay curve. lorfeldt et al. (17) dem-
onstrated that femoral vein flow measured using this tech-
nique agrees closely with leg flow determined using injec-
tion of indocyanine green into the femoral artery with sampling 
from the femoral vein. 
In our laboratory, flow determined using the bolus in-
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jectate technique correlated closely with known flow rates 
(0.2 to 0.6 liter/min, r = 0.99) evaluated using a closed 
loop system in which 37°C water was continuously circu-
lated through 7 mm polyethylene tubing using a roller pump. 
In studies in humans, the coefficient of variation of duplicate 
flow measurements made sequentially in patients during the 
same exercise test was 9 ± 10% at rest and 16 ± 12% 
during exercise. The variation during exercise is expected 
given the normal phasic alterations in flow. Therefore, mul-
tiple flow measurements are always made during any given 
work load and the average flow is calculated. During each 
exercise test in this study, each patient had 13 to 20 leg 
blood flow measurements made resulting in administration 
of 32 to 50 ml of iced dextrose. Thermodilution cardiac 
output determination was not performed, so that the total 
amount of dextrose administered to each patient during the 
entire study was small. 
Reproducibility studies. The period between exercise 
tests was at least 3 hours. To assure that exercise results 
are reproducible when repeated at this interval, reproduc-
ibility measurements were made in six patients. At peak 
exercise, the following key measurements were found to be 
reproducible: systemic oxygen consumption (V02) (1,041 ± 
553 versus 1,000 ± 526 mllmin; first versus second ex-
ercise), arterial lactate (35.5 ± 9.4 versus 32.3 ± 9.5 
mg/dl), leg flow (3.15 ± 1.40 versus 3.21 ± 1.57 li-
ters/min), femoral vein lactate (44.6 ± 11.5 versus 43.9 
± 16.4 mg/dl) and leg arteriovenous oxygen difference 
(13.23 ± 1.34 versus 12.94 ± 1.72 mlldl). 
Measured variables. Hemoglobin concentration was 
measured by Coulter Counter; hemoglobin oxygen satura-
tion was measured with a cooximeter (Instrumentation Lab-
oratories) precalibrated with human blood. Blood oxygen 
content was calculated as the product of hemoglobin, 1.34 
ml oxygen/g hemoglobin and percent oxygen saturation. 
Oxygen extraction was calculated as the ratio of the arte-
riovenous oxygen difference and arterial oxygen content. 
Cardiac output was calculated from the Fick principle as 
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systemic oxygen uptake/systemic arteriovenous oxygen dif-
ference. Systemic vascular resistance was calculated as mean 
blood pressure/cardiac output. 
Leg vascular resistance was calculated as (arterial 
pressure - femoral vein pressure )/Ieg flow. Leg oxygen 
consumption (V02) was calculated as the product of femoral 
vein flow and the arteriovenous oxygen difference across 
the leg. Blood for lactate determination was deproteinized 
with cold perchloric acid and assayed with a spectropho-
tometric technique (22). Normal values at rest for this tech-
nique in our laboratory are 3 to 12 mg/dl. Leg lactate release 
was calculated as leg blood flow x (femoral vein - arterial 
lactate concentration). It should be noted that leg flow, 
oxygen extraction and lactate data were not obtained si-
multaneously. Therefore, calculation of leg oxygen uptake 
and lactate release assumes that leg flow remained relatively 
constant during exercise. In support of this assumption, we 
have observed that flow increases abruptly with the onset 
of exercise and stabilizes within 30 to 45 seconds. 
Statistical methods. Values are presented as mean ± 
SO. Differences between measurements at rest and maximal 
exercise were compared using the paired Student's t test for 
all variables except leg resistance. The distribution of leg 
resistances was nonparametric. Therefore, differences in 
this variable were compared using the rank sum test, the 
nonparametric analog of the paired t test. A probability of 
less than 0.05 was considered significant. 
Results 
The effect of captopril on systemic and regional variables 
is summarized in Tables I and 2 and illustrated in Figures 
I and 2. All the exercise data represent information accu-
mulated at the highest exercise time common to both control 
and captopril exercise tests. 
Effect of captopril at rest. At supine rest before the 
administration of captopril, the cardiac output was 3.6 ± 
1.3 liters/min, pulmonary wedge pressure 24 ± 9 mm Hg, 
Table 1. Effects of Captopril on Systemic Hemodynamic and Metabolic Responses to Exercise 
HR BP CO PWP SVR V02 Oxygen Extraction Lactate 
(beats/min) (mmHg) (liters/min) (mm Hg) (U) (ml/min) (%) (mg/dl) 
Control 
Supine 87 ± II 90 ± 7 3.6 ± 1.3 24 ± 9 27± 10 253 ± 50 46 ± 12 
Bicycle 99 ± 16 90 ± 7 3.4 ± l.l 24 ± II 29 ± II 285 ± 58 55 ± II 12 ± 3 
Peak exercise:j: 122 ± 15 99 ± 10 5.8 ± 2.2 30 ± 9 20 ± 10 716 ± 189 77 ± 7 27 ± 9 
Captopril 
Supine 85 ± 10 75 ± lOt 3.9 ± 1.4* 19 ± lOt 22 ± lOt 259 ± 37 42 ± 9 
Bicycle 94 ± 14 77± lOt 3.4 ± 1.0 22 ± II 24 ± 9t 300 ± 47 55 ± 8 13 ± 3 
Peak exercise+ 116 ± 16 85 ± 12t 5.7 ± 2.0 27 ± 13* 16 ± 5* 702 ± 161 75 ± 6 25 ± 8 
*p < 0.05 compared with control; tp < 0.01 compared with control; :j:measured at the highest work time common to both control and captopril 
exercise. BP = blood pressure; CO = cardiac output; HR = heart rate; PWP = pulmonary wedge pressure; SVR = systemic vascular resistance; 
V02 = oxygen uptake. 
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Table 2. Effects of Captopril on Leg Hemodynamic and Metabolic Responses to Exercise 
Femoral Venous-Arterial Leg 
Leg Leg Oxygen Vein Lactate Lactate 
Leg Flow§ Leg V02§ Resistance§ Extraction Lactate Difference Release 
(liters/min) (mllmin) (U) (%) (mg/dl) (mg/dl) (mg/min) 
Control 
Supine 0.3 :±: 0.1 25 :±: 8 258 :±: 115 46 :±: 15 
Bicycle 0.3 :±: 0.1 30 :±: 14 340 :±: 136 63 :±: 10 14 :±: 3 2 :±: 2 8 :±: 9 
Peak exercise:j: 2.0:±: 0.9 261 :±: 104 68 :±: 69 83 :±: 6 41 :±: 12 15 :±: 6 269 :±: 149 
Captopril 
Supine 0.4 :±: 0.1 22 :±: 9 173 :±: 67t 37 :±: 17* 
Bicycle 0.3 :±: 0.2 35 :±: 18 244 :±: 92t 63 :±: 10 14 :±: 3 I:±: I 5 :±: 6 
Peak exercise:j: 2.0 :±: l.l 281 :±: 157 45 :±: 29t 83 :±: 5 37 :±: 9 12 :±: 6 227 :±: 151 
*p < 0.05 compared with control; tp < 0.01 compared with control; :j:measured at the highest work time common to both control and captopril 
exercise; §Ieg flow, V02 and resistance were measured in only 9 of the 12 patients. 
systemic vascular resistance 27 ± 10 U, leg flow 0.3 ± 
0, I liters/min and leg vascular resistance 258 ± 115 U, 
Right atrial pressure was 8 ± 6 mm Hg, Administration of 
captopril decreased systemic resistance by 20 ± 15% to 22 
± 10 U (p < 0,003) and decreased leg resistance by 25 ± 
36% to 173 ± 67 U (p < 0,006) (Fig, I). This vasodilation 
was associated with an increase in the cardiac output to 3.9 
± 1.4 liters/min (p < 0.03 versus control) and a decrease 
in the pulmonary wedge pressure to 19 ± 10 mm Hg (p < 
0,005 versus control) but with no change in leg blood flow. 
On mounting the bicycle before administration of cap-
topril, systemic vascular resistance increased from 27 ± 10 
to 29 ± II U and leg resistance from 258 ± 115 to 
340 ± 136 U, Administration of captopril decreased upright 
systemic and leg resistances to an extent proportional to that 
observed at supine rest, but did not decrease the upright 
pulmonary wedge pressure or increase the upright cardiac 
output. 
Effect of captopril during exercise. During control ex-
ercise, patients exercised for 4.1 ± 2,2 minutes to a max-
imal \102 of 726 ± 213 mllmin. After captopril adminis-
Figure 1. Effect of captopril on systemic and leg vascular resis-
tance, Exercise data were obtained at the highest exercise time 
common to both tests, MAX = maximal. 
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tration, there was no significant change in either maximal 
\102 (727 ± 186 mllmin) or maximal exercise duration (4,0 
± 1,7 minutes), Exercise duration was identical in nine 
patients, increased modestly in one and decreased in two. 
To examine the effect of captopril on exercise data, vari-
ables were compared at the highest exercise time common 
to both tests, At this exercise point, captopril decreased 
systemic vascular resistance by 19 ± 15% (20 ± 10 to 
16 ± 5 U, P < 0,02) and decreased leg resistance by 25 
± 23% (68 ± 69 to 45 ± 29 U, P < 0,01) (Fig, 1), 
Pulmonary wedge pressure was decreased from 30 ± 9 to 
27 ± 13 mm Hg (p < 0.02). In contrast, there was no 
change in cardiac output, systemic V02 , arterial lactate, leg 
blood flow, leg V02 , leg oxygen extraction, femoral-arterial 
lactate difference or leg lactate release (Fig. 2). 
Subgroup responses to captopril (Table 3). Systemic 
vascular resistance at the highest work time common to both 
tests was decreased by 20% or more in five and less than 
20% in seven patients. In the five patients with a 20% or 
greater decrease in systemic resistance, there was no change 
in maximal V02 (691 ± 247 to 747 ± 255, P = NS). 
When compared at the highest work time common to both 
tests, captopril also produced no change in metabolic vari-
ables in either group, 
Discussion 
Vasoconstrictor and vasodilator influences during ex-
ercise. Heart failure is accompanied by a reduction in blood 
flow to peripheral tissues both at rest and during exercise . 
This reduced flow leads to the recruitment of a number of 
compensatory vasoconstrictor mechanisms designed to pro-
tect the systemic blood pressure and redistribute blood flow 
to vital organs, These compensatory mechanisms include 
activation of the sympathoadrenal (23) and renin-angio-
tensin systems (8-11), 
At rest, when peripheral tissue oxygen demands are small, 
activation of these vasoconstrictor mechanisms is largely 
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beneficial. During exercise, however, these vasoconstrictor 
mechanisms may be deleterious. Exercise further activates 
both the sympathoadrenal and renin-angiotensin systems in 
an attempt to sustain the blood pressure and redistribute 
flow most efficiently. From the standpoint of the blood flow 
to working skeletal muscle, this activation on the one hand 
serves to sustain muscle perfusion pressure, a key deter-
minant of muscle flow. However, this activation also exerts 
vasoconstrictor influences on arterioles in working muscle 
and thereby may interfere with muscle vasodilation, the 
other key determinant of muscle flow. 
The extent to which vasodilation is affected is determined 
by the balance between local vasodilatory factors and 
vasoconstrictor influences. Studies in humans and experi-
mental animals (14,24,25) have shown that constrictor re-
sponses in muscle to sympathetic nerve activation, norepi-
nephrine administration and angiotensin administration are 
attenuated during exercise by local vasodilatory factors. In 
normal subjects, the balance between these two competing 
influences is such that constrictor influences are markedly 
attenuated (24). However, abnormally high levels of 
vasoconstrictor activity, as occur in patients with heart fail-
ure, may be sufficient to interfere with metabolic vasodi-
lation and thereby impair blood flow to working skeletal 
muscle (14,25,26). 
Effect of the renin-angiotensin system on muscle vaso-
dilation. In this study, we sought to determine whether 
the renin-angiotensin system interferes with blood flow to 
working skeletal muscle in patients with heart failure. Nu-
merous prior observations suggest that the renin-angiotensin 
Table 3. Comparison of Systemic and Regional Measurements at the Highest Exercise Work 
Time Common to Both Control and Captopril Exercise in Patients With a 20% or Greater 
Decrease in Systemic Vascular Resistance Versus Patients With a Less Than 20% Decrease 
Systemic Leg Lactate 
Decrease in Systemic YO, Arterial Lactate Femoral-Arterial Release 
Resistance (mllmin) (mg/dl) Lactate (mg/dl) (mg/min) 
20% or greater (n = 5) 
Control 690 ± 246 28 ± 5 11.9 ± 4.4 198 ± 149 
Captopril 691 ± 209 26 ± 9 9.4 ± 3.7 204 ± 166 
Less than 20% (n = 7) 
Control 737 ± 147 26 ± 9 16.4 ± 5.9 378 ± 105 
Captopril 712 ± 129 24 ± g 14.0 ± 6.9 311 ± 64 
All comparisons of control versus captopril data were not significant. 
JACC Vol. 6. NO.3 
September 1985:556-63 
system is frequently more activated in such patients than in 
normal subjects. Plasma renin levels are frequently higher 
than normal at rest (8,9) and become even more elevated 
during exercise (10, II, Mark Creager, personal commu-
nication). Blockade of the renin-angiotensin system produces 
systemic vasodilation at rest and during exercise in such 
patients (27-30), further supporting the presence of 
vasoconstrictor influences mediated by angiotensin II. Fi-
nally, angiotensin II is known to be a potent vasoconstrictor 
of skeletal muscle arterioles by both a direct effect (12-14) 
and augmentation of sympathetically mediated vasocon-
striction (15). 
To determine whether the renin-angiotensin system in-
terferes with blood flow to working skeletal muscle, we 
examined the effect of captopril, an angiotensin converting 
enzyme inhibitor, on leg resistance, leg blood flow and leg 
lactate release during maximal upright bicycle exercise. Leg 
resistance and blood flow were used as indexes of skeletal 
muscle resistance and flow, respectively; flow to nonmus-
cular tissue makes up only a small portion of leg blood flow 
during exercise (31). Systemic and leg oxygen uptake and 
leg lactate release were used as indexes of the adequacy of 
oxygen delivery to working muscle (32,33). To evaluate 
changes in these variables during exercise, the variables 
were compared at the highest work time common to both 
control and captopril exercise. Exercise level influences muscle 
blood flow and metabolism. Therefore, comparison of data 
at different work times would leave uncertain whether any 
change observed is due to captopril or differences in work 
load. 
During control exercise, all patients developed metabolic 
changes suggesting impaired blood flow to working skeletal 
muscle. Specifically, patients were limited by fatigue at 
reduced maximal oxygen uptakes of 10.7 ± 3.1 mllmin per 
kg, the normal maximal oxygen uptake being greater than 
20 to 25 mllmin per kg (34). The leg oxygen extraction and 
leg lactate release noted at maximal exercise were markedly 
increased above levels observed in normal subjects at com-
parable work loads (35,36). The limb vascular resistance 
noted at maximal exercise was also higher than levels ob-
served by us in patients with normal exercise capacity (4), 
suggesting reduced limb vasodilation. 
Administration of captopril reduced systemic and limb 
vascular resistance both at rest and during exercise. This 
vasodilation was accompanied by improved pump function 
at rest as evidence by a reduction in the pulmonary wedge 
pressure and increase in the cardiac output. However, we 
found no evidence that flow or metabolic responses to ex-
ercise were improved. Maximal exercise duration and max-
imal oxygen uptake were not increased and the arterial lac-
tate response to exercise was not decreased. When measured 
at identical peak exercise times, cardiac output, leg blood 
flow, leg oxygen uptake and leg lactate release were all 
unchanged. 
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These findings reinforce prior observations indicating that 
the renin-angiotensin system frequently contributes to sys-
temic vascular resistance both at rest and during exercise in 
patients with heart failure (27-30). This vasoconstrictor ef-
fect in turn supports the arterial blood pressure at rest and 
during exercise. Of greater interest, however, is that our 
findings suggest that this vasconstrictor effect of the renin-
angiotensin system does not interfere with blood flow to 
working skeletal muscle. If angiotensin II did interfere with 
muscle flow, one would expect that captopril would increase 
muscle flow and oxygen uptake and reduce muscle lactate 
release. These changes were not observed in either the total 
study group or the subgroup of patients with the greatest 
decrease in systemic vascular resistance with captopril and 
presumably, therefore, the highest angiotensin II levels. A 
prior study by Kugler et al. (30) also failed to demonstrate 
any acute change in maximal oxygen uptake after captopril 
administration in patients with heart failure. 
The decrease in leg vascular resistance noted during 
exercise after captopril administration most likely repre-
sented an autoregulatory response on the part of active mus-
cle. Captopril produced a substantial decrease in mean ar-
terial pressure during exercise. Because muscle flow and 
muscle V02 apparently remained constant, metabolic fac-
tors in working muscle most likely produced arteriolar di-
lation to keep muscle flow commensurate with muscle ox-
ygen demand. The decrease in leg resistance may also at 
least in part have been due to a reduction in vasoconstriction 
in nonexercising tissues of the leg. 
During exercise, the overall circulatory effect of the renin-
angiotensin system in patients with severe heart failure is, 
therefore, probably not detrimental with respect to nutri-
tional blood flow to skeletal muscle and may in some re-
spects be beneficial. During exercise, this system helps to 
increase vascular resistance in nonexercising vascular beds 
and thereby optimize the perfusion pressure of exercising 
muscle. This beneficial systemic effect appears to occur 
without adverse regional effects on blood flow to working 
skeletal muscle. 
Potential limitations. This conclusion must be viewed 
within the context of several potential limitations. The use 
of skeletal muscle glycolysis as a marker of blood flow to 
working muscle is supported by prior observations that re-
ducing muscle flow augments glycolysis (32,33). Never-
theless, glycolysis occurs normally in well oxygenated 
working muscle and is affected by pH and substrate avail-
ability (37,38). We cannot totally exclude the possibility 
that changes in these other variables affected our results but 
doubt that such changes occur. Another limitation is that 
captopril inhibits an enzyme responsible for the degradation 
of bradykinin (39). Because bradykinin is a potent vaso-
dilator, it is possible that accumulation of this hormone 
contributed to the observed effects of captopril. A further 
potential concern with captopril relates to the dosing sched-
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ule utilized in this study. To avoid marked hypotension, we 
chose to administer captopril in sequential doses depending 
on the hemodynamic response rather than to administer a 
single fixed dose. This approach was taken to avoid marked 
hypotension, which would have precluded repeat exercise 
and, more important, might offset a potentially beneficial 
regional effect of converting enzyme inhibition by reducing 
muscle perfusion pressure. Therefore, it is possible that 
angiotensin-converting enzyme inhibition was not complete 
in all patients. 
One last concern relates to our not having obtained plasma 
renin levels during exercise. An alternative approach to this 
study would have been to measure renin levels at rest and 
during exercise in patients with heart failure and then to 
perform studies only on those subjects who showed high 
renin levels during exercise. We elected not to take this 
approach for several reasons. First, prior investigators (8,9) 
have demonstrated that the hemodynamic response to cap-
topril correlates with plasma renin levels. Second, it remains 
uncertain to what extent plasma renin activation during ex-
ercise provides a valid reflection of the impact of the renin-
angiotensin system on the muscle vasculature. Angiotensin 
II has different vasoactive effects depending on vascular 
sodium content and adrenergic activity (13,15). Therefore, 
even normal angiotensin II levels may have adverse 
vasoconstrictor effects during exercise depending on the 
accompanying neurohumoral and vascular environment. In 
addition, measurement of renin levels during exercise may 
not necessarily reflect either systemic or local vascular an-
giotensin II levels. During the brief exercise periods un-
dertaken in this study, a steady state of angiotensin may not 
have been achieved. 
Clinical Implications 
The maximal aerobic exercise capacity of patients with 
heart failure is frequently limited by reduced skeletal muscle 
blood flow. Therefore, to be able to design methods for 
improving the maximal exercise capacity of such patients, 
it is important to identify the mechanism responsible for 
this reduced flow. The present study suggests that direct 
interference by angiotensin II with vasodilation in working 
muscle is probably not an important contributor. Prior ob-
servations from our laboratory (2) suggest that the reduced 
cardiac output noted during exercise in patients with heart 
failure is also not a key contributor. Blood flow to working 
muscle is increased during exercise as a result of vasodi-
lation within muscle coupled with augmentation of muscle 
perfusion pressure, produced by vasoconstriction in nonex-
ere ising tissues and an increase in cardiac output. Therefore, 
reduced flow to working skeletal muscle in patients with 
heart failure is probably due to an intrinsic impairment of 
vasodilation in muscle, impaired vasodilation produced by 
sympathetic nerve activation or an abnormality of blood 
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pressure regulation during exercise. Studies are needed to 
determine which of these abnormalities is operative. Studies 
will also be needed to clarify the factor or factors that produce 
the abnormality. In this regard, the renin-angiotensin system 
still may prove to contribute indirectly to altered muscle 
flow in heart failure. 
In summary, this study suggests that the renin-angio-
tensin system contributes to systemic vascular resistance 
both at rest and during exercise in patients with severe heart 
failure but does not directly interfere with blood flow to 
working skeletal muscle. 
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